Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial

Abstract Previous studies showed encouraging efficacy of alternating FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). This phase 2 trial (NCT04324476) aimed to evaluate efficacy and safety of alternating modified CAPOX (capecitabine and oxaliplatin)/modified CAPIRI (capecitabine and irinoteca...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheng Li, Xiaoyou Li, Hanfeng Xu, Jiayuan Huang, Jingni Zhu, Ying Peng, Jun Bao, Liangjun Zhu
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-02048-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items